[Correspondence] Dacomitinib in NSCLC: a positive trial with little clinical impact – Authors' reply

Alfredo Addeo has noted two issues in our trial1 of dacomitinib versus gefitinib in patients with non-small-cell lung cancer (NSCLC): the fact that we did not discuss central nervous system (CNS) penetration by dacomitinib and the similar progression-free survival in the Asian and non-Asian intention-to-treat (ITT) subpopulations.

http://ift.tt/2zNJYPC